Prescription software firm Pear Therapeutics to go public via $1.6 billion SPAC deal, harnessing 3 FDA-authorized products and 14 candidates

By SharpBrains | June 23, 2021

Pear Ther­a­peu­tics to Go Pub­lic in Rough­ly $1.6 Bil­lion SPAC Deal (The Wall Street Jour­nal): Med­ical tech­nol­o­gy com­pa­ny Pear Ther­a­peu­tics Inc. has agreed to go pub­lic by merg­ing with a blank-check com­pa­ny with ties to the Pritzk­er Vlock Fam­i­ly Office, bet­ting on the grow­ing role of pre­scrip­tion dig­i­tal ther­a­peu­tics. The pro­posed merg­er would give the…

Read More

Ohio joins Indiana and Kentucky in funding Pear Therapeutics’ digital addiction treatments

By SharpBrains | April 26, 2021

Ohio is third state to fund Pear’s dig­i­tal ther­a­peu­tics to tack­le addic­tion (phar­mafo­rum): The com­pa­ny has been push­ing for more reim­burse­ment of its three mar­ket­ed DTx prod­ucts in the US fol­low­ing a first FDA approval in 2017. Pear said that the Ohio Depart­ment of Men­tal Health and Addic­tion Ser­vices (OhioMHAS) and Recov­ery­Ohio are pro­vid­ing access to…

Read More

Novartis dissolves agreement to market Pear Therapeutics’ prescription digital therapeutics for substance/ opioid abuse

By SharpBrains | October 25, 2019

_______________ As San­doz returns mar­ket­ing rights for dig­i­tal ther­a­peu­tics to Pear, what does it mean for co-pro­­mote arrange­ments? (MM&M): “San­doz, the gener­ics divi­sion of Novar­tis, is alter­ing com­mer­cial course, return­ing mar­ket­ing duties for two pre­scrip­tion dig­i­tal ther­a­peu­tics (DTx) back to Pear Ther­a­peu­tics. The move, which some had antic­i­pat­ed, comes 18 months after the two signed…

Read More

Can digital Cognitive Behavioral Therapy (CBTi) become the universal first-line treatment for insomnia?

By SharpBrains | August 13, 2019

__________ Pear Ther­a­peu­tics’ dig­i­tal insom­nia ther­a­peu­tic will put FDA’s Pre­Cert frame­work through its paces (Mobi­Health­News): “Pre­scrip­tion dig­i­tal ther­a­peu­tics com­pa­ny Pear Ther­a­peu­tics announced late last week that it has filed an FDA mar­ket­ing autho­riza­tion for Som­ryst, its dig­i­tal cog­ni­tive behav­ioral ther­a­py for the treat­ment of adults with chron­ic insom­nia and depres­sion. While an approval from the…

Read More

Pear Therapeutics raises $50M to develop and market a portfolio of digital therapeutics for mental health

By SharpBrains | January 4, 2018

___ Pear Ther­a­peu­tics rakes in $50M to devel­op addi­tion­al dig­i­tal ther­a­peu­tics (Mobi­Health­News): “Boston- and San Fran­­cis­­co-based Pear Ther­a­peu­tics, mak­er of a pre­scrip­tion dig­i­tal ther­a­peu­tic plat­form, announced today the clo­sure of $50 mil­lion in Series B fund­ing. The round was led by Sin­­ga­­pore-based invest­ment com­pa­ny Temasek, with par­tic­i­pa­tion from return­ing investors 5AM Ven­tures, Arbore­tum Ven­tures, and…

Read More